Chau T. Dang, MD, discusses the rationale of the phase 2 BERENICE trial in early-stage HER2-positive breast cancer.
Chau Dang, MD, Memorial Sloan Kettering Westchester
Advertisement
Articles by Chau Dang, MD, Memorial Sloan Kettering Westchester
Advertisement
Latest Updated Articles
Q&A: Practical Considerations in HER2+ Breast CancerPublished: September 24th 2020 | Updated:
Dual HER2-Targeted Approaches in Breast CancerPublished: September 24th 2020 | Updated:
The Impact of Subcutaneous Option for HER2+ BCPublished: September 24th 2020 | Updated:
Efficacy of Fixed-Dose Subcutaneous Therapy for HER2+ BCPublished: September 24th 2020 | Updated:
Historic Perspectives on HER2+ Breast CancerPublished: September 24th 2020 | Updated:
Administration of Dual HER2-Targeted Therapy in BCPublished: September 24th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
The OncFive: Top Oncology Articles for the Week of 1/25
3
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
4
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
5